SG11202102987VA - Thieno[3,2-b]pyridine derivatives as udp glycosyltransferase inhibitors and methods of use - Google Patents

Thieno[3,2-b]pyridine derivatives as udp glycosyltransferase inhibitors and methods of use

Info

Publication number
SG11202102987VA
SG11202102987VA SG11202102987VA SG11202102987VA SG11202102987VA SG 11202102987V A SG11202102987V A SG 11202102987VA SG 11202102987V A SG11202102987V A SG 11202102987VA SG 11202102987V A SG11202102987V A SG 11202102987VA SG 11202102987V A SG11202102987V A SG 11202102987VA
Authority
SG
Singapore
Prior art keywords
thieno
methods
pyridine derivatives
udp glycosyltransferase
glycosyltransferase inhibitors
Prior art date
Application number
SG11202102987VA
Inventor
Sungtaek Lim
Jr Robert H Barker
Mary A Cromwell
Elina Makino
Bradford Hirth
John JIANG
Sachin Maniar
Mark Munson
Yong-Mi Choi
Sukanthini Thurairatnam
Kwon Yon Musick
James Pribish
Michael Angelastro
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of SG11202102987VA publication Critical patent/SG11202102987VA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202102987VA 2018-10-01 2019-10-01 Thieno[3,2-b]pyridine derivatives as udp glycosyltransferase inhibitors and methods of use SG11202102987VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862739405P 2018-10-01 2018-10-01
PCT/US2019/054085 WO2020072504A1 (en) 2018-10-01 2019-10-01 Thieno[3,2-b]pyridine derivatives as udp glycosyltransferase inhibitors and methods of use

Publications (1)

Publication Number Publication Date
SG11202102987VA true SG11202102987VA (en) 2021-04-29

Family

ID=68296740

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202102987VA SG11202102987VA (en) 2018-10-01 2019-10-01 Thieno[3,2-b]pyridine derivatives as udp glycosyltransferase inhibitors and methods of use

Country Status (15)

Country Link
US (1) US11098056B2 (en)
EP (1) EP3861000A1 (en)
JP (1) JP2022508523A (en)
KR (1) KR20210087033A (en)
CN (1) CN113423711B (en)
AU (1) AU2019355870B2 (en)
BR (1) BR112021005914A2 (en)
CA (1) CA3114722A1 (en)
CO (1) CO2021005738A2 (en)
IL (1) IL281811A (en)
MA (1) MA53043A1 (en)
MX (1) MX2021003794A (en)
SG (1) SG11202102987VA (en)
TW (1) TWI821426B (en)
WO (1) WO2020072504A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022222458A1 (en) * 2021-02-19 2023-08-24 Kalvista Pharmaceuticals Limited Factor xiia inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3763156A (en) * 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
JP2003528810A (en) 1999-08-04 2003-09-30 ミレニアム ファーマスーティカルズ インク Melanocortin-4 receptor binding compounds and methods of use
US7375125B2 (en) * 1999-08-04 2008-05-20 Ore Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
US8354408B2 (en) * 2007-11-15 2013-01-15 Ym Biosciences Australia Pty Ltd N-containing heterocyclic compounds
BRPI1007923A2 (en) * 2009-02-06 2020-08-25 Elan Pharmaceuticals, Inc compound, pharmaceutical composition, methods for treating a neurodegenerative disease, and for reducing the concentration of p-cjun in brain tissue of an individual in need thereof, use of a compound, and, in vitro method
JP2014511391A (en) * 2011-03-07 2014-05-15 フォンダッツィオーネ・テレソン TFEB phosphorylation inhibitors and uses thereof
EA037663B1 (en) * 2015-01-16 2021-04-28 Те Дженерал Хоспитал Корпорейшн COMPOUNDS FOR IMPROVING mRNA SPLICING
BR112018012914B1 (en) * 2015-12-22 2023-04-18 SHY Therapeutics LLC COMPOUND, USE OF A COMPOUND AND PHARMACEUTICAL COMPOSITION
JP7164774B2 (en) * 2016-05-05 2022-11-02 ビアル-アール・アンド・ディ・インベストメンツ・ソシエダーデ・アノニマ Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in treating medical disorders
WO2017214505A1 (en) * 2016-06-10 2017-12-14 Biomarin Pharmaceutical Inc. Ceramide galactosyltransferase inhibitors for the treatment of disease
WO2018118838A1 (en) * 2016-12-20 2018-06-28 Biomarin Pharmaceutical Inc. Ceramide galactosyltransferase inhibitors for the treatment of disease
EA201992343A1 (en) * 2017-05-04 2020-04-16 Гленмарк Фармасьютикалс С.А. SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH-OXIDASE INHIBITORS
IL271230B1 (en) * 2017-06-21 2024-02-01 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease

Also Published As

Publication number Publication date
JP2022508523A (en) 2022-01-19
CO2021005738A2 (en) 2021-05-10
CN113423711B (en) 2024-03-15
EP3861000A1 (en) 2021-08-11
CN113423711A (en) 2021-09-21
MA53043A1 (en) 2022-08-31
AU2019355870A1 (en) 2021-05-20
MX2021003794A (en) 2021-09-08
BR112021005914A2 (en) 2021-06-29
CA3114722A1 (en) 2020-04-09
AU2019355870B2 (en) 2023-11-16
TW202035419A (en) 2020-10-01
US20200102324A1 (en) 2020-04-02
KR20210087033A (en) 2021-07-09
US11098056B2 (en) 2021-08-24
WO2020072504A1 (en) 2020-04-09
TWI821426B (en) 2023-11-11
IL281811A (en) 2021-05-31

Similar Documents

Publication Publication Date Title
HUE061989T2 (en) Substituted thieno[2,3-d]pyrimidine derivatives as inhibitors of menin-mll and methods of use
IL281127A (en) Pyrazolo[3,4-b]pyridine compounds as inhibitors of tam and met kinases
ZA201904737B (en) Pyridine derivative as ask1 inhibitor and preparation method and use thereof
LT3237423T (en) Thieno[2,3-c]pyrrol-4-one derivatives as erk inhibitors
EP3644771A4 (en) Nicotine salts and methods of making and using same
HK1244804A1 (en) 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
PT3712152T (en) 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
PL3371185T3 (en) 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
IL251780B (en) 5-(3-hydroxy-propyn-1-yl)-3-(2-amino-pyrimidinyl)-1hpyrrolo[2,3-c]pyridine derivatives and pharmaceutical compositions comprising them
ME03672B (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
EP3421472A4 (en) Nitrogen heterocyclic tryptamine ketone derivative and application as ido1 and/or tdo inhibitor
EP3630772A4 (en) Methods of making and using pde9 inhibitors
EP3897630A4 (en) Thienopyridine inhibitors of ripk2
IL275290B2 (en) Combination treatments comprising administration of 1h-pyrazolo[4,3-b]pyridines
HUE056882T2 (en) Combination treatments comprising administration of 1h-pyrazolo[4,3-b]pyridines
EP3689871A4 (en) 4,6,7-trisubstituted 1,2-dihydropyrrol[3,4-c]pyridin/pyrimidin-3-one derivative and use
EP3448375A4 (en) Benzoylglycine derivatives and methods of making and using same
IL281811A (en) Thieno[3,2-b]pyridine derivatives as udp glycosyltransferase inhibitors and methods of use
EP3405576A4 (en) Methods and compositions using rna interference for inhibition of kras
EP3612513A4 (en) Type ii topoisomerase inhibitors and methods of making and using thereof
EP3515447A4 (en) Uridine nucleoside derivatives, compositions and methods of use
EP3553060A4 (en) Polycrystalline mesylate of phosphodiesterase type 5 inhibitor, preparation method therefor, and application thereof
EP3650450A4 (en) Crystal form ii of thienopyridine derivative bisulfate and preparation method therefor and use thereof
HUE038944T2 (en) Thiochromeno[2,3-c]quinolin-12-one derivatives and their use as topoisomerase inhibitors
IL287417A (en) Cytidine derivatives and methods of forming cytidine derivatives